Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Will Launch Generic Valtrex After GlaxoSmithKline Patent Expires In 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian firm also licensed two process patents related to the herpes virus treatment after the firms resolved a patent infringement dispute.

You may also be interested in...



Ranbaxy/GSK Partnership Yields First Drug Candidate

Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.

Generic Valtrex Launch Likely Delayed Pending Resolution Of GSK/Ranbaxy Suit

GlaxoSmithKline says it will file a motion for preliminary injunction to block Ranbaxy from launching generic valacyclovir.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel